Precision Optics Stock Price, News & Analysis

Precision Optics Corporation (NASDAQ: POCI), a specialized manufacturer of advanced optical instruments for medical and defense/aerospace sectors, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025.

The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the virtual event. Interested participants can access the webcast through the conference website or arrange individual meetings with management through Lytham Partners.

Precision Optics Corporation (NASDAQ: POCI) reported Q3 FY2025 financial results with significant challenges and strategic developments. Revenue declined to $4.2 million from $5.2 million year-over-year, with production revenue at $3.3 million and engineering revenue at $0.9 million. The company faced setbacks with gross margins dropping to 10.0% from 35.5%, resulting in a net loss of ($2.1) million. Despite challenges, POCI secured a Main Purchase Agreement with a top-tier aerospace company, guaranteeing minimum purchases of nearly $4 million annually through 2026. The company launched the Unity Imaging Platform for endoscopic imaging devices and completed a $5.1 million common stock offering. Production issues with a single-use cystoscope line were resolved, with doubled throughput after February restart. Management expects improved Q4 performance with sequential revenue growth and break-even or better adjusted EBITDA.

Precision Optics Corporation (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, has scheduled a conference call to discuss its third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET.

The company will release its financial results and file its 10-Q after market close on the same day. Interested parties can join the call by dialing (844) 735-3662 or (412) 317-5705, or access the live webcast at the provided link. A replay will be available for seven days.

Precision Optics (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025.

The presentation is scheduled for Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at Track 3 – Chablis in the Paris Hotel & Casino, Las Vegas. Dr. Joe Forkey, CEO, will lead the presentation and conduct a Q&A session.

The company will also hold one-on-one meetings with interested parties on April 24, 2025. Investors can access the live presentation through the provided webcast link and schedule 1x1 meetings through Planet MicroCap representatives or the company's investor relations team.

Precision Optics (NASDAQ: POCI) has signed a Main Purchase Agreement with a leading aerospace company, solidifying their commercial partnership that began in September 2023. The agreement showcases significant growth with:

• $3.1 million in new orders received during the current calendar year
• Total program backlog of $6.6 million to be delivered over the next 12 months
• Nearly $4 million per year in minimum purchase commitments through calendar 2026

To meet increased demand, POCI has doubled its clean room production line capacity. The partnership leverages Precision Optics' proprietary manufacturing technology for commercial aerospace applications.

Precision Optics (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, has announced its participation in the Lytham Partners 2025 Industrials & Basic Materials Investor Summit.

The company will engage in a webcasted fireside chat scheduled for April 1, 2025, at 3:30 p.m. ET. The virtual event will be accessible through the conference homepage and a dedicated company link, with replay options available afterward.

Interested investors can request one-on-one meetings following the event by contacting Lytham Partners representatives directly.

Precision Optics (NASDAQ: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has appointed Joseph P. 'JJ' Pellegrino, Jr. to its Board of Directors. Pellegrino will serve as Chairman of the Board's Audit Committee.

Pellegrino brings significant experience from his recent role as CFO of LeMaitre Vascular (2007-2025), where he continues as a board member. His career includes positions as Executive VP of Finance at LeMaitre, SVP of Operations at Zoots, and investment banking analyst at Lehman Brothers. He holds degrees from Harvard College and Harvard Business School.

The appointment coincides with Peter Anania's retirement from the Board, who joined in October 2021 following Precision Optics' acquisition of Lighthouse Imaging, where he served as President and Chairman.

Precision Optics (NASDAQ: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has announced key changes to its Board of Directors. Buell Duncan, former Chief Marketing Officer of IBM Software, Cloud, Data and AI businesses, has been appointed to the board, bringing extensive executive leadership experience from his 28-year tenure at IBM (1992-2020).

Duncan currently serves as a Portfolio Advisor and Partner with Iron Gate Capital, a venture capital firm focused on early-growth B2B technology companies. He is also a Board observer of SHARE Mobility and Respondology, and a Strategic Advisor to several technology companies.

Concurrent with Duncan's appointment, Dr. Richard Miles, who joined the board in November 2005, has announced his retirement after nearly 20 years of service.

Precision Optics (NASDAQ: POCI) has successfully closed a registered direct offering of common stock, raising $5.1 million in gross proceeds through the sale of 1,272,500 shares at $4.00 per share. The company expects net proceeds of approximately $5.0 million after deducting offering expenses.

The funds will be allocated to three main purposes: repaying certain indebtedness, expanding facilities to support anticipated growth, and general working capital. The offering was conducted under an effective shelf registration statement on Form S-3, which was declared effective on June 14, 2024, with a prospectus supplement filed on February 20, 2025.